- Home
- ADSE vs CRMD Comparison
ADSE vs CRMD Comparison
Compare ADSE & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADSE | CRMD |
|---|---|---|
| Founded | 1980 | 2006 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.8M | 876.7M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | ADSE | CRMD |
|---|---|---|
| Price | $12.40 | $11.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 25.1K | ★ 2.9M |
| Earning Date | 12-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.25 |
| Revenue | $53,275,396.00 | ★ $214,303,672.00 |
| Revenue This Year | $219.58 | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | ★ N/A | $5.10 |
| Revenue Growth | N/A | ★ 1647.67 |
| 52 Week Low | $7.89 | $5.60 |
| 52 Week High | $16.35 | $17.43 |
Technical Indicators
Market Signals| Indicator | ADSE | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 61.66 |
| Support Level | $12.23 | $10.90 |
| Resistance Level | $12.67 | $12.10 |
| Average True Range (ATR) | 0.59 | 0.50 |
| MACD | 0.03 | 0.24 |
| Stochastic Oscillator | 82.56 | 83.07 |
Price Performance
Historical ComparisonAbout ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.